The global CAR-T Cell therapy market is anticipated to grow over 20 percent CAGR during the forecasting period and likely to touch nearly US$ 8 Billion landmarks in 2028. The year 2017 was the milestone year for the CAR-T therapy as US FDA has approved two CAR-T cell therapies Kymriah in August 2017 and Yescarta in October 2017. In July 2020, US FDA has approved 3rd CAR-cell therapy Tecartus for the treatment of relapsed or refractory mantle cell lymphoma (MCL). To date, it is the only approved therapy for the treatment of MCL across the world.
In the context of antigens, CD-19, CD-20 and CD22 are considered potential targets by healthcare companies and research organizations. Antigen CD-19 holds the majority of the share in CAR-T clinical trials. All three approved Kymriah, Yescarta and Tecartus CAR-T cell therapy is based on antigen CD-19. At present total of 164 CAR-T studies are enrolled in the United States National Library of Medicine for the CD19 antigen across the various parts of the world. The United States and China hold the majority share of these studies in 2020.
MNG Tracker report titled “Global CAR-T Cell Therapy Market by Application (Acute Lymphoblastic Leukaemia (ALL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM)), by Regions (North America, Europe, Asia Pacific, Latin America Middle East, Africa), by Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvIII, Others) Market Products (Yescarta, Kymriah)” provides an all-encompassing insight of Chimeric Antigen Receptor (CAR-T) cell therapy industry.
The objective of this study is to analyze Global CAR-T Cell Therapy market by two prospective - CAR-T cell therapy market and pharmaceutical company’s initiatives. Under the market section, we identifying the market growth potentials and market value by CAR-T cell therapy applications, antigens, regions and marketed products, rules & regulations, reimbursements policy in various countries, approved and marketed therapy, growth drivers, challenges; whereas in company section our objectives are: to find out the key companies latest initiatives, company CAR-T clinical trials, product candidate/pipeline in this market place.
This 257 pages study report with 46 Figures & 5 Tables studies the Global CAR-T Cell Therapy market from 11 view points:
- Market and Forecast
- Market Share and Forecast
- By Therapeutic Applications CAR-T Cell Therapy - Market & Forecast
- By Antigens CAR-T Cell Therapy - Market & Forecast
- By Regions CAR-T Cell Therapy - Market & Forecast
- By Marketed Products CAR-T Cell Therapy - Market & Forecast
- CAR-T Cell Therapy Product Approvals by Regulatory Body Globally
- CAR-T Cell Therapy - Rules & Regulations
- CAR-T Cell Therapy - Reimbursement
- CAR-T Cell Therapy - Growth Drivers & Challenges
- CAR-T Cell Therapy - Company Profiles (Company overview, latest initiatives, CAR-T clinical trials, product candidate/pipeline)
Global CAR-T Cell Therapy Market - By Therapeutic Applications
- Acute Lymphoblastic Leukaemia (ALL)
- Diffuse Large B Cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Chronic Lymphocytic Leukaemia (CLL)
- Multiple Myeloma (MM)
Global CAR-T Cell Therapy Market - By Antigens
- CD19
- CD20
- GD2
- CD22
- CD30
- CD33
- HER2
- MESO
- EGFRvIII
- Others
Global CAR-T Cell Therapy Market – Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Global CAR-T Cell Therapy Market – Marketed & Potential Products
- Yescarta
- Kymriah
- Tecartus
Key Company Profile - Company Overview, Latest Initiatives, CAR-T Clinical Trials/Product Candidate/Pipeline
- Novartis
- Gilead Sciences (Kite Pharma)
- Bristol-Myers Squibb (Celgene)
- JW Therapeutics
- Celyad Oncology
1 Market Definition
2 Research and Methodology
3 Executive Summary
4 CAR-T Cell Therapy - Market Overview
5 Global CAR-T Cell Therapy Market & Forecast (2017 – 2028)
6 Global CAR-T Cell Therapy Market Share & Forecast (2017 - 2028)
6.1 By Therapeutic Applications
6.2 By Regions
6.3 By Target Antigens
7 By Therapeutic Applications - Global CAR-T Cell Therapy Market (2018 -2028)
7.1 Acute Lymphoblastic Leukaemia (ALL)
7.2 Diffuse Large B Cell Lymphoma (DLBCL) Diffuse Large B Cell Lymphoma (DLBCL)
7.3 Follicular Lymphoma (FL) Follicular Lymphoma (FL)
7.4 Mantle Cell Lymphoma (MCL) Mantle Cell Lymphoma (MCL)
7.5 Chronic Lymphocytic Leukaemia (CLL)
7.6 Multiple Myeloma (MM) multiple myeloma (MM)
8 By Regions - Global CAR-T Cell Therapy Market (2017 -2028)
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Latin America
8.5 Middle East
8.6 Africa
9 By Target Antigens - Global CAR-T Cell Therapy Market (2017 -2028)
9.1 CD19
9.2 CD20
9.3 GD2
9.4 CD22
9.5 CD30
9.6 CD33
9.7 HER2
9.8 MESO
9.9 EGFRvIII
9.10 Others
10 Marketed Products - Global CAR-T Cell Therapy Market
10.1 Kymriah (Tisagenlecleucel)
10.1.1 Mechanism of Action
10.1.2 Dosing and Administration
10.1.3 Kymriah Cost in Approved Countries
10.1.4 Kymriah Global Sales (2018 - 2028)
10.2 Yescarta (Axicabtagene ciloleucel)
10.2.1 Mechanism of Action
10.2.2 Dosing and Administration
10.2.3 Yescarta Cost in Approved Countries
10.2.4 Yescarta Global Sales (2018 - 2028)
10.3 Tecartus (Brexucabtagene Autoleucel)
10.3.1 Mechanism of Action
10.3.2 Dosing and Administration
10.3.3 Tecartus Cost in Approved Countries
11 Partnerships & Deals - Global CAR-T Cell Therapy Market
12 Reimbursement - Global CAR-T Cell Therapy Market & Forecast
12.1 United States
12.2 Europe
12.2.1 France
12.2.2 Germany
12.2.3 Italy
12.2.4 Spain
12.2.5 United Kingdom
13 Regulations - Global CAR-T Cell Therapy Market & Forecast
13.1 United States
13.2 Europe
13.3 China
14 Reimbursement - Global CAR-T Cell Therapy Market & Forecast
14.1 FDA Approved CAR T-Cell Therapies
14.2 European Commission/European Medicines Agency Approved CAR T-Cell Therapies
14.3 Others
15 Growth Drivers - Global CAR-T Cell Therapy Market & Forecast
15.1 Positive Reimbursement Decisions
15.2 The Rise of CAR-T Therapy in Oncology
16 Challenges - Global CAR-T Cell Therapy Market & Forecast
16.1 High Upfront Cost
16.2 Complex Manufacturing and Supply Chain
16.3 Limited Number of Certified Academic Medical Centers (AMCs)
16.4 Reimbursement Challenges for CAR –T Cell Therapy
17 Company Profiles - Global CAR-T Cell Therapy Market & Forecast
17.1 Novartis
17.1.1 Company Overview
17.1.2 Company Initiatives/News
17.1.3 Company CAR-T Clinical Trials
17.2 Gilead Sciences (Kite Pharma)
17.2.1 Company Overview
17.2.2 Company Initiatives/News
17.2.3 Company CAR-T Clinical Trials
17.3 Bristol-Myers Squibb (Celgene)
17.3.1 Company Overview
17.3.2 Company Initiatives/News
17.3.3 Company CAR-T Clinical Trials
17.4 JW Therapeutics
17.4.1 Company Overview
17.4.2 Company Initiatives/News
17.4.3 Product Candidate
17.5 Celyad Oncology
17.4.1 Company Overview
17.4.2 Company Initiatives/News
17.4.3 Company CAR-T Cell Therapy Pipeline
Figure-1 Global - CAR-T Cell Therapy Market (Million US$), 2017 - 2020
Figure-2 Global - Forecast for CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-3 Global - CAR-T Cell Therapy Market Application Share (Percent), 2018 - 2020
Figure-4 Global – Forecast for CAR-T Cell Therapy Market Application Share (Percent), 2021 - 2028
Figure-5 Global - CAR-T Cell Therapy Market Regions Share (Percent), 2017 - 2020
Figure-6 Global – Forecast for CAR-T Cell Therapy Market Share (Percent), 2021 - 2028
Figure-7 Global - Acute Lymphoblastic Leukaemia (ALL) CAR-T Market (Million US$), 2018 - 2020
Figure-8 Global - Forecast for Acute Lymphoblastic Leukaemia (ALL) CAR-T Market (Million US$), 2021 - 2028
Figure-9 Global - Diffuse Large B Cell Lymphoma (DLBCL) CAR-T Market (Million US$), 2019 - 2020
Figure-10 Global - Forecast for Diffuse Large B Cell Lymphoma (DLBCL) CAR-T Market (Million US$), 2021 - 2028
Figure-11 Global - Follicular Lymphoma (FL) CAR-T Market (Million US$), 2019 - 2020
Figure-12 Global - Forecast for Follicular Lymphoma (FL) CAR-T Market (Million US$), 2021 - 2028
Figure-13 Global - Mantle Cell Lymphoma (MCL) CAR-T Market (Million US$), 2019 - 2020
Figure-14 Global - Forecast for Mantle Cell Lymphoma (MCL) CAR-T Market (Million US$), 2021 - 2028
Figure-15 Global - Chronic Lymphocytic Leukaemia (CLL) CAR-T Market (Million US$), 2019 - 2020
Figure-16 Global - Forecast for Chronic Lymphocytic Leukaemia (CLL) CAR-T Market (Million US$), 2021 - 2028
Figure-17 Global - Multiple Myeloma (MM) CAR-T Market (Million US$), 2019 - 2020
Figure-18 Global - Forecast for Multiple Myeloma (MM) CAR-T Market (Million US$), 2021 - 2028
Figure-19 North America - CAR-T Cell Therapy Market (Million US$), 2017 - 2020
Figure-20 North America – Forecast for CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-21 Europe - CAR-T Cell Therapy Market (Million US$), 2018 - 2020
Figure-22 Europe – Forecast for CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-23 Asia Pacific - CAR-T Cell Therapy Market (Million US$), 2018 - 2020
Figure-24 Asia Pacific – Forecast for CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-25 Latin America - CAR-T Cell Therapy Market (Million US$), 2018 - 2020
Figure-26 Latin America – Forecast for CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-27 Middle East - CAR-T Cell Therapy Market (Million US$), 2019 - 2020
Figure-28 Middle East – Forecast for CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-29 Africa - CAR-T Cell Therapy Market (Million US$), 2019 - 2020
Figure-30 Africa – Forecast for CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-31 Global - CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2020
Figure-32 Global – Forecast for CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2021 - 2028
Figure-33 Global – Present & Forecast for CD20 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
Figure-34 Global – Forecast for GD2 Antigen CAR-T Cell Therapy Market (Million US$), 2025 - 2028
Figure-35 Global – Forecast for CD22 Antigen CAR-T Cell Therapy Market (Million US$), 2023 - 2028
Figure-36 Global – Forecast for CD30 Antigen CAR-T Cell Therapy Market (Million US$), 2024 - 2028
Figure-37 Global – Forecast for CD33 Antigen CAR-T Cell Therapy Market (Million US$), 2025 - 2028
Figure-38 Global – Forecast for HER2 Antigen CAR-T Cell Therapy Market (Million US$), 2025 - 2028
Figure-39 Global – Forecast for MESO Antigen CAR-T Cell Therapy Market (Million US$), 2025 - 2028
Figure-40 Global – Forecast for EGFRvIII Antigen CAR-T Cell Therapy Market (Million US$), 2025 - 2028
Figure-41 Global – Forecast for Others Antigen CAR-T Cell Therapy Market (Million US$), 2025 - 2028
Figure-42 Global – Kymriah Sales (Million US$), 2018 -2020
Figure-43 Global – Forecast for Kymriah Sales (Million US$), 2021 - 2028
Figure-44 Global - Yescarta Sales (Million US$), 2018 - 2020
Figure-45 Global – Forecast for Yescarta Sales (Million US$), 2021 - 2028
Figure-46 Celyad Oncology – CAR-T Cell Therapy Pipeline, 2020
Table-1 Global - CAR-T Cell Therapy Market Target Antigen Share (Percent), 2017 - 2020
Table-2 Global – Forecast for CAR-T Cell Therapy Market Target Antigen Share (Percent), 2021 - 2028
Table-3 Novartis – CAR-T Cell Therapy Studies Status, 2020
Table-4 Gilead Science/Kite – CAR-T Cell Therapy Studies Status, 2020
Table-5 Bristol-Myers Squibb/Celgene – CAR-T Cell Therapy Studies Status, 2020
 
Thank you for showing interest in our Research Report - Global CAR-T Cell Therapy Market (Applications, World Regions, Antigens, Marketed Products) & Forecast to 2028
Please fill up the form and specify your research requirement.